<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1677">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04535154</url>
  </required_header>
  <id_info>
    <org_study_id>PROLUN</org_study_id>
    <nct_id>NCT04535154</nct_id>
  </id_info>
  <brief_title>Patient-reported Outcomes and Lung Function After Hospitalization for COVID-19</brief_title>
  <acronym>PROLUN</acronym>
  <official_title>Patient-reported Outcomes and Lung Function After Hospitalization for COVID-19</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Akershus</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Oslo University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ostfold Hospital Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Haukeland University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>St. Olavs Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The National Association for Heart and Lung Disease, Jessheim, Norway</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Akershus</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A multicenter prospective cohort study performed at 6 major teaching hospitals in Southern
      Norway to study patient reported outcomes, lung function and pulmonary CT in patients at 3
      and 12 months after hospitalization for coronavirus disease 2019 (COVID-19).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This cohort study aim to describe the Natural course of COVID-19 disease in an consecutive
      and unselected cohort of Norwegians that have been hospitalized.

      In addition to the primary and secondary outcomes related to PROMS, lung function and
      pulmonary CT, the study also have several substudies: Cardiology: The study includes
      echocardiography, 24-h electrocardiography and cardiopulmonary exercise test.

      ENT: The study includes CT of head sinuses and patient-reported sleep disturbances and nose
      symptoms in a subgroup of patients.

      Laboratory: Analyses of common markers of inflammation and cardiac biomarkers.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">March 31, 2020</start_date>
  <completion_date type="Anticipated">June 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Forced vital capacity</measure>
    <time_frame>3 months</time_frame>
    <description>L</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Forced vital capacity</measure>
    <time_frame>12 months</time_frame>
    <description>L</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Gas diffusion capacity of carbon monoxide</measure>
    <time_frame>3 months</time_frame>
    <description>mmol/kPa*min</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Gas diffusion capacity of carbon monoxide</measure>
    <time_frame>12 months</time_frame>
    <description>mmol/kPa*min</description>
  </primary_outcome>
  <primary_outcome>
    <measure>modified Medical Respiratory Council Dyspnea Scale</measure>
    <time_frame>6 weeks</time_frame>
    <description>Unit</description>
  </primary_outcome>
  <primary_outcome>
    <measure>modified Medical Respiratory Council Dyspnea Scale</measure>
    <time_frame>3 months</time_frame>
    <description>Unit</description>
  </primary_outcome>
  <primary_outcome>
    <measure>modified Medical Respiratory Council Dyspnea Scale</measure>
    <time_frame>12 months</time_frame>
    <description>Unit</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Parenchymal opacities of the lungs</measure>
    <time_frame>3 months</time_frame>
    <description>Number of opacities in one lung zone</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Parenchymal opacities of the lungs</measure>
    <time_frame>12 months</time_frame>
    <description>Number of opacities in one lung zone</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Forced expiratory capacity during 1st second of expiration</measure>
    <time_frame>3 months</time_frame>
    <description>L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Forced expiratory capacity during 1st second of expiration</measure>
    <time_frame>12 months</time_frame>
    <description>L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FEV1/FVC</measure>
    <time_frame>3 months</time_frame>
    <description>Percentage</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FEV1/FVC</measure>
    <time_frame>12 months</time_frame>
    <description>Percentage</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gas diffusion capacity adjusted for alveolar ventilation (KCO)</measure>
    <time_frame>3 months</time_frame>
    <description>mmol/kPa*min*L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gas diffusion capacity adjusted for alveolar ventilation (KCO)</measure>
    <time_frame>12 months</time_frame>
    <description>mmol/kPa*min*L</description>
  </secondary_outcome>
  <enrollment type="Actual">264</enrollment>
  <condition>Covid19</condition>
  <condition>Lung Function Decreased</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No interventions</intervention_name>
    <description>No interventions</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Consecutive patients hospitalized who have been hospitalized for COVID-19
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Discharged before June 1 2020 after hospitalization at participating hospital for
             COVID-19

        Exclusion Criteria:

          -  Age &lt; 18 years

          -  Dementia

          -  Living outside hospital catchment area

          -  Participation in WHO COVID-19 clinical trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gunnar Einvik, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Akershus</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dept Pulmonary Medicine</name>
      <address>
        <city>LÃ¸renskog</city>
        <state>Viken</state>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>August 29, 2020</study_first_submitted>
  <study_first_submitted_qc>August 31, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 1, 2020</study_first_posted>
  <last_update_submitted>August 31, 2020</last_update_submitted>
  <last_update_submitted_qc>August 31, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 1, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital, Akershus</investigator_affiliation>
    <investigator_full_name>Gunnar Einvik</investigator_full_name>
    <investigator_title>Primary Investigator</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>May 22, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/54/NCT04535154/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

